Sign in to view content

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

Katherine E Talcott, MD

Video
Published 2021

Related

What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019
A Randomized Trial Comparing Suprachoroidal Injection of Triamcinolone and Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema
Murat Oncel, MD, FASRS
Annual Meeting Talks
2024
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021

Category: Diabetic Retinopathy

See more